Promore Pharma comments on media reports about ensereptide

STOCKHOLM, 31 March, 2021 - Promore Pharma provides clarification regarding media data on previous studies with ensereptide (PXL01) regarding skin scarring

In a commentary on today's publication of Promore Pharma's new strategy focusing on scars on the skin, the media has directed a historical review of research results published in 2012, where it was referred to that a study with ensereptide against scarring did not reach its primary goals. The company therefore wants to clarify the following:

The company has not previously conducted any study regarding the effect of ensereptide to prevent scarring of the skin. However, the company has previously conducted a clinical study with ensereptide concerning scarring between tendon and tendon sheath in the hand (PHSU02).

The company also wants to clarify that during the implementation of PHSU02, a first analysis was carried out after three months of follow-up where the primary study goal did not achieve a statistically verifiable difference between ensereptide and placebo. However, after 6 and 12 months of follow-up, it was found that the study essentially achieved its goals, including a statistically significant treatment effect of ensereptide. These results were never communicated in separate press releases since the company was not public at the time. However, these results have been published in a scientific article (Wiig et al, 2014*) and were described in Promore Pharma's prospectus** in connection with the initial public offering in 2017.

*Wiig ME, Dahlin LB, Fridén J, Hagberg L, Larsen SE, et al. (2014) PXL01 in Sodium Hyaluronate for Improvement of Hand Recovery after Flexor Tendon Repair Surgery: Randomized Controlled Trial. PLoS ONE 9(10): e110735.

**https://www.promorepharma.com/sv/wp-content/uploads/sites/3/2017/06/Inbjudan-till-forvarv-av-units-i-Promore-Pharma-publ.pdf

For additional information, please contact

Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com

Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com

Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: certifiedadviser@penser.se

Promore Pharma in brief

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.

Attachments

Promore Pharma comments on media reports about ensereptide